CINGW
Cingulate Inc. WarrantsNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-1.73
Beta
-0.81
52W High
$0.17
52W Low
$0.02
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Cingulate Inc. Warrants
Cingulate Inc. Warrants represent a unique investment vehicle linked to a biopharmaceutical firm dedicated to pioneering innovative therapies for Attention Deficit Hyperactivity Disorder (ADHD) and associated disorders. The company is advancing a promising lead product designed to enhance treatment efficacy and tolerability, strategically addressing significant unmet needs in a burgeoning market. With a solid pipeline and well-defined growth initiatives, Cingulate demonstrates substantial potential for delivering attractive returns, positioning itself as an appealing choice for institutional investors seeking to diversify within the healthcare landscape.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-9.77M |
| EBITDA | $-19.40M |
| Operating Margin | 0.00% |
| Return on Equity | -450.60% |
| Return on Assets | -83.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.35 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $11.29M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 5/5/2026